Market open
ATAI Life Sciences/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Ticker
$ATAI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
54
ISIN
NL0015000DX5
Website
ATAI Metrics
BasicAdvanced
$286M
-
-$0.91
-
-
Price and volume
Market cap
$286M
52-week high
$2.57
52-week low
$1.03
Average daily volume
1.5M
Financial strength
Current ratio
4.069
Quick ratio
3.446
Long term debt to equity
7.806
Total debt to equity
17.513
Interest coverage (TTM)
-30.75%
Management effectiveness
Return on assets (TTM)
-25.83%
Return on equity (TTM)
-79.43%
Valuation
Price to revenue (TTM)
126.28
Price to book
1.66
Price to tangible book (TTM)
1.7
Growth
Revenue change (TTM)
572.56%
Earnings per share change (TTM)
327.65%
3-year revenue growth (CAGR)
55.45%
3-year earnings per share growth (CAGR)
-13.49%
What the Analysts think about ATAI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
ATAI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATAI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATAI News
AllArticlesVideos
atai Life Sciences builds clinical momentum in first quarter of 2025
Proactive Investors·1 day ago
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
GlobeNewsWire·1 day ago
atai Life Sciences doses first patient in Phase 2 social anxiety trial
Proactive Investors·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $286M as of May 15, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of May 15, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) does not currently have a Beta indicator.